EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Liver Tumor Microenvironment in Hepatocellular Carcinoma: Comparisons with Intrahepatic Cholangiocarcinoma and Therapeutic Implications

Kizuki Yuza iD, Jun Kawashima, Miho Akabane, Timothy M Pawlik iD

Cancers · 20.08.2026 · 18 (16) · 2696

DOI: 10.3390/cancers18162696 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 20.08.2026. Verfasst von Kizuki Yuza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The liver is an immunologically distinctive organ. Portal blood continuously delivers gut-derived antigens and microbial products, requiring hepatic immunity to balance surveillance with restraint. In hepatocellular carcinoma (HCC), this physiology is commonly overlaid by chronic injury, inflammation, and fibrosis, so the background liver forms part of the disease context in which the tumor microenvironment (TME) develops. This review synthesizes how cellular architecture, tumor-intrinsic programs, and structural, metabolic, and microbial conditions interact to shape immune evasion and heterogeneity. HCC provides the principal evidence base, with intrahepatic cholangiocarcinoma (iCCA) used as a structured, biologically distinct comparator. We organize therapies by the microenvironmental barriers they are intended to modify and distinguish established clinical efficacy from evidence that the proposed mechanisms mediate treatment benefit. Single-cell and spatial studies have resolved cellular states and spatial arrangements, including onco-fetal endothelial–myeloid neighborhoods and a macrophage–fibroblast boundary band separating lymphocyte-rich stroma from malignant tissue. These patterns operate within fibrotic and metabolically altered tissue and vary by etiology, spatial context, and tumor type. Vascular endothelial growth factor blockade with immune checkpoint inhibition and dual checkpoint blockade are established first-line options in advanced HCC. Chemo-immunotherapy is established in biliary tract cancer, and IDH1 inhibition has established efficacy in IDH1-mutant cholangiocarcinoma. Myeloid- and stroma-directed strategies, natural-product approaches, and engineered-cell therapies remain preclinical or early clinical. None of the pivotal trials tested whether the proposed microenvironmental mechanism mediated treatment benefit. The liver TME informs treatment selection without yet determining it.

Schlagwörter

Stichwörter der Autor:innen

gut–liver axishepatocellular carcinomaimmune checkpoint inhibitorsimmune evasionintrahepatic cholangiocarcinomaliver tumor microenvironmentmetabolic reprogrammingonco-fetal reprogramming

Autor:innen und Institutionen

  • Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA.
  • Department of Gastroenterological Surgery, Yokohama City University, Yokohama 236-0004, Japan.

ORCID-Profile: Kizuki Yuza, Timothy M Pawlik

Zitieren

APA

Yuza, K., Kawashima, J., Akabane, M., & Pawlik, T. M. (2026). The Liver Tumor Microenvironment in Hepatocellular Carcinoma: Comparisons with Intrahepatic Cholangiocarcinoma and Therapeutic Implications. Cancers, 18(16), 2696. https://doi.org/10.3390/cancers18162696

Vancouver

Yuza K, Kawashima J, Akabane M, Pawlik TM. The Liver Tumor Microenvironment in Hepatocellular Carcinoma: Comparisons with Intrahepatic Cholangiocarcinoma and Therapeutic Implications. Cancers. 2026;18(16):2696. doi:10.3390/cancers18162696

BibTeX
@article{Yuza2026,
  author = {Yuza, Kizuki and Kawashima, Jun and Akabane, Miho and Pawlik, Timothy M},
  title = {The Liver Tumor Microenvironment in Hepatocellular Carcinoma: Comparisons with Intrahepatic Cholangiocarcinoma and Therapeutic Implications},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2696},
  doi = {10.3390/cancers18162696}
}
Kostenlos starten →